SYDNEY Australia 20 December 2016: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today announced encouraging early results for the company's lead product candidate RECCE® 327 as a potential anti-viral agent.
RECCE® 327 is a synthetic compound currently being developed to treat sepsis (blood poisoning from bacteria) with a near term goal of filing an investigational new drug (IND) application with the US Food & Drug Administration (FDA) in 2017
Recce Limited Executive Chairman Dr Graham Melrose said while the company was focused on establishing manufacturing and compiling pre-clinical data for its IND application in 2017, it was also developing, at lower priority, complementary capabilities of the RECCE® 327 to augment its central capability as an antibiotic. This additional data is aimed at broadening and potentially strengthening Recce’s IND submission as a new class of antibiotic.
The recent study using RECCE® 327 in a mouse model for virus induced human influenza demonstrated strong correlation of efficacy from the doses administered.
Dr Melrose said the study conducted by an independent contract research organisation (CRO) in the US observed two groups of 10 mice, both infected with influenza virus and beginning to display symptoms of the illness.
The data showed a difference between Group 1 which was treated with RECCE® 327 at a dose rate of 140 milligrams/kilograms of mouse during each of the first five days and Group 2 which received no treatment (see below).
This result warrants further investigation to determine a comparison of the optimal dosage amounts and timing, against efficacies of commercially established drugs.
“Our pre-clinical programs are on track and we are working towards bringing a potential treatment for sepsis and other infections to Phase 1 clinical trials in 2017,” Dr Melrose said.
For further information please visit www.recce.com.au.
About Recce Ltd
Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.
The discovery of RECCE® 327’s in vitro capabilities against cancer and viruses (as well as bacteria-superbugs) has greatly increased the value of the Company’s technology, especially in view of the synergism between antibiotic/anti-cancer properties and anti-viral/anti-cancer properties.
Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies, and potential financial returns, from manufacture and distribution of its products in about 80% of the world’s pharmaceutical markets for antibiotics.
To receive the latest information on Recce - Subscribe here
Issued on for and on behalf of Recce by Instintif Partners.
For more information please contact firstname.lastname@example.org.
Sue CharlesManaging Partner